论文部分内容阅读
目的:通过乙肝病毒(HBV)核酸定量、HBV血清学标志物(HBV-M)、ALT、AST指标的监测,观察慢性乙型肝炎患者服用拉米呋啶的疗效。方法:选择986例慢性乙型肝炎患者,治疗组786例,服用拉米呋啶治疗药物(100mg/d),对照组200例,未服用治疗药物,两组定期采血作HBV-DNA定量、HBV-M、肝功能检测。结果:治疗1年后治疗组391例HBV-DNA阴转(<104cps/ml)(49.7%),对照组8例阴转(4%);治疗组786例ALT、AST异常者703例恢复正常(89.4%),对照组200例18例恢复正常(9.0%);治疗组HBeAg/Anti-HBe转换84例(19.2%),HBeAg阴转62例(14.2%)。对照组5例HBeAg/Anti-HBe转换(4.2%)。结论:拉米呋啶能有效抑制HBV的复制,降低ALT和AST,促进HBeAg/Anti-HBe转换及HBeAg阴转。
OBJECTIVE: To observe the curative effect of taking lamivudine in patients with chronic hepatitis B through the monitoring of the quantitative of hepatitis B virus (HBV) nucleic acid, the detection of HBV serological markers (HBV-M), ALT and AST. Methods: A total of 986 patients with chronic hepatitis B were enrolled. 786 patients in the treatment group were treated with lamivudine (100 mg / d), 200 in the control group without medication. The two groups were routinely sampled for HBV DNA quantification and HBV -M, liver function test. Results: One year after treatment, 391 cases of HBV-DNA were negative (<104cps / ml) in treatment group (49.7%) and 8 cases of negative conversion (4%) in control group. (89.4%). The control group (18 cases) returned to normal (9.0%) in 200 cases. In the treatment group, 84 cases (19.2%) had HBeAg / Anti-HBe conversion and 62 cases (14.2%) had HBeAg negative conversion. In the control group, 5 cases of HBeAg / Anti-HBe conversion (4.2%). Conclusion: Lamivudine can effectively inhibit HBV replication, reduce ALT and AST, promote HBeAg / Anti-HBe conversion and HBeAg negative conversion.